Jahrsdörfer B - Search Results

1

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.

Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Bonig H, et al. Among authors: jahrsdorfer b. J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1. J Transl Med. 2023. PMID: 37990219 Free PMC article.

2

CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.

Jahrsdörfer B, Weiner GJ. Jahrsdörfer B, et al. Curr Opin Investig Drugs. 2003 Jun;4(6):686-90. Curr Opin Investig Drugs. 2003. PMID: 12901226 Review.

3

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

Jahrsdörfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ. Jahrsdörfer B, et al. Blood. 2006 Oct 15;108(8):2712-9. doi: 10.1182/blood-2006-03-014001. Epub 2006 Jun 29. Blood. 2006. PMID: 16809616 Free PMC article.

4

Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia.

Jahrsdörfer B, Blackwell SE, Wooldridge JE, Taylor CM, Weiner GJ. Jahrsdörfer B, et al. Oligonucleotides. 2005 Spring;15(1):51-9. doi: 10.1089/oli.2005.15.51. Oligonucleotides. 2005. PMID: 15788900

5

Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.

Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G. Jahrsdörfer B, et al. J Leukoc Biol. 2002 Jul;72(1):83-92. J Leukoc Biol. 2002. PMID: 12101266

6

Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity.

Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Link BK, Weiner GJ. Jahrsdörfer B, et al. Leukemia. 2005 May;19(5):759-66. doi: 10.1038/sj.leu.2403694. Leukemia. 2005. PMID: 15759034

7

B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.

Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G. Jahrsdorfer B, et al. Clin Cancer Res. 2005 Feb 15;11(4):1490-9. doi: 10.1158/1078-0432.CCR-04-1890. Clin Cancer Res. 2005. PMID: 15746051

8

Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.

Jahrsdörfer B, Weiner GJ. Jahrsdörfer B, et al. Semin Oncol. 2003 Aug;30(4):476-82. doi: 10.1016/s0093-7754(03)00236-7. Semin Oncol. 2003. PMID: 12939716 Review.

9

S100A4 and uric acid promote mesenchymal stromal cell induction of IL-10+/IDO+ lymphocytes.

Eisenbacher JL, Schrezenmeier H, Jahrsdörfer B, Kaltenmeier C, Rojewski MT, Yildiz T, Beyer T, Erle A, Wiegmann DS, Grassl S, Hang R, Körper S, Wiesneth M, Lotze MT, Lotfi R. Eisenbacher JL, et al. Among authors: jahrsdorfer b. J Immunol. 2014 Jun 15;192(12):6102-10. doi: 10.4049/jimmunol.1303144. Epub 2014 May 2. J Immunol. 2014. PMID: 24795458 Clinical Trial.

10

CD27(+)IgD(-) B cells in the peripheral blood of colorectal cancer patients: on anti-tumor or tumor-protective mission?

Jahrsdörfer B, Lindner S, Hagn M, Schrezenmeier H. Jahrsdörfer B, et al. Oncoscience. 2014 Sep 9;1(9):558-9. doi: 10.18632/oncoscience.78. eCollection 2014. Oncoscience. 2014. PMID: 25594063 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page